RSV (Respiratory Syncytial Virus) is the most common cause of lower respiratory tract infections in infants, causing 2.2m annual hospitalisations, and its seasonal epidemic places a significant burden on healthcare systems every year. Despite years of research, there has been no prophylactic solution to protect a broad population of infants against RSV.
However, with the recent approval of new immunization solutions against RSV, several national immunization agencies are starting to develop recommendations for RSV prevention which encompass both traditional vaccines and newer immunization technologies, such as preventative RSV monoclonal antibodies.
To support the implementation of this unprecedented programme which would secure wide population access and significantly reduce the RSV burden on individuals and healthcare systems, it is crucial that national recommendation bodies and medical societies continue to assess how these solutions can be made available and consider the appropriate policy recommendations to support their inclusion in the routine immunization calendar. It is only via a well-prepared and coordinated implementation programme that the significant RSV burden on infants, families and healthcare systems can be alleviated.